Pipeline for individually tailoring new treatments for relapsed, intractable chronic lymphocytic leukemia and multiple myeloma
- Prosjektnummer
- 2015031
- Ansvarlig person
- Kjetil Taskén
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Åpen prosjektstøtte
- Helsekategori
- Blood, Cancer
- Forskningsaktivitet
- 5. Treatment Developement
No
Sigrid Skånland har hatt forskningsopphold på Memorial Sloan Kettering Cancer Centre høst 2022 (men dette er jo lenge etter utløpet av prosjektet).
NO
NEI
NEi
Standardized assays to monitor drug sensitivity in hematologic cancers.
Cell Death Discov 2023 Dec 01;9(1):435. Epub 2023 des 1
PMID: 38040674
A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine.
Cell Death Discov 2023 Apr 13;9(1):125. Epub 2023 apr 13
PMID: 37055391 - Inngår i doktorgradsavhandlingen
Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines.
Front Oncol 2022;12():1040730. Epub 2022 nov 29
PMID: 36523963
Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically.
Mol Oncol 2022 Mar;16(6):1241. Epub 2022 mar 12
PMID: 35148457
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.
Mol Oncol 2022 Mar;16(5):1153. Epub 2021 des 18
PMID: 34861096
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.
Clin Cancer Res 2022 Oct 14;28(20):4444.
PMID: 35998013
A national precision cancer medicine implementation initiative for Norway.
Nat Med 2022 May;28(5):885.
PMID: 35513529
Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models.
Trends Pharmacol Sci 2022 Nov;43(11):973. Epub 2022 sep 23
PMID: 36163057
Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development.
Biochem J 2022 Oct 28;479(20):2219.
PMID: 36305711
Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case.
Haematologica 2022 Aug 01;107(8):1994. Epub 2022 aug 1
PMID: 35236056
B cell signalling pathways-New targets for precision medicine in chronic lymphocytic leukaemia.
Scand J Immunol 2020 Nov;92(5):e12931. Epub 2020 okt 10
PMID: 32640099
An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL.
Leukemia 2020 02;34(2):478-487. Epub 2019 aug 30
PMID: 31471562
EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology.
SLAS Discov 2019 03;24(3):398-413. Epub 2019 jan 7
PMID: 30616481
The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
J Immunol 2019 03 01;202(5):1397-1405. Epub 2019 jan 28
PMID: 30692213
Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia.
Oncotarget 2018 Feb 06;9(10):9273-9284. Epub 2018 jan 4
PMID: 29507689
Cryopreservation of primary B cells minimally influences their signaling responses.
Sci Rep 2018 Dec 05;8(1):17651. Epub 2018 des 5
PMID: 30518828
Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery.
J Vis Exp 2018 10 04. Epub 2018 okt 4
PMID: 30346411
Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice.
Leukemia 2017 Oct;31(10):2114-2121. Epub 2017 feb 24
PMID: 28232741
Phosphoprotein Detection by High-Throughput Flow Cytometry.
Methods Mol Biol 2016;1355():275-90.
PMID: 26584933
Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells.
Haematologica 2016 Feb;101(2):e59-62. Epub 2015 nov 20
PMID: 26589914
Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units.
Front Immunol 2016;7():222. Epub 2016 jun 8
PMID: 27375620
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.
Cancer Immunol Immunother 2015 Oct;64(10):1271-86. Epub 2015 jun 28
PMID: 26122357
Cancer immunity and immune evasion mechanisms. In Biomarkers of the Tumor Microenvironment.
2016. Accepted for publication.
Application of drug sensitivity screening in B-cell malignancies for informing precision medicine strategies
- Disputert:
- juni 2022
- Hovedveileder:
- Kjetil Tasken
- Leonardo Miranda Santana Postdoktorstipendiat (annen finansiering)
- Henrik Bendiksen Prosjektdeltaker
- Judith Staerk Prosjektdeltaker
- Camila Vicencio Esguerra Prosjektdeltaker
- Mariaserena Giliberto Doktorgradsstipendiat (annen finansiering)
- Theresa Dorothee Ahrens Postdoktorstipendiat (annen finansiering)
- Andrea Cremaschi Postdoktorstipendiat (annen finansiering)
- Manuela Karola Zucknick Prosjektdeltaker
- Arnoldo Frigessi Prosjektdeltaker
- Camilla Victoria Myklebust Doktorgradsstipendiat (annen finansiering)
- Deepak Balaji Thimiri Govinda Raj Postdoktorstipendiat (finansiert av denne bevilgning)
- Dong Wang Postdoktorstipendiat (finansiert av denne bevilgning)
- Sigrid Strand Skånland Forsker (annen finansiering)
- Fredrik Hellem Schjesvold Prosjektdeltaker
- Geir Erland Tjønnfjord Prosjektdeltaker
- Ludvig Andre Munthe Hovedveileder
- Kjetil Tasken Prosjektleder
- Camila V. Esguerra Prosjektdeltaker
- Bjørn Tore Gjertsen Prosjektdeltaker
- Alvaro Kohn Luque Prosjektdeltaker
- Manuela Karola Zucknick Prosjektdeltaker
- Sowmja Subbana Prosjektdeltaker
- Ida Kristin Myhrvold Prosjektdeltaker
- Anna Maria Parente Ribes Prosjektdeltaker
- Camilla Myklebust Prosjektdeltaker
- Deepak Balaji Thimiri Govindaraj Postdoktorstipendiat
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport